Clinical characteristics of patients with SLE
| N (95) | % | |
| Disease duration: median (range) | 15.0 years (0.2–38.7) | |
| ANA positive | 94 | 99 |
| dsDNA positive | 77 | 81 |
| Anti-Smith positive | 14 | 15 |
| APLS antibodies (any) | 55 | 58 |
| APLS antibody triple positive | 5 | 5 |
| History of cerebrovascular disease | 12 | 13 |
| History of seizures | 8 | 8 |
| History of cranial neuropathy | 5 | 5 |
| SLEDAI-2K score: median (range) | 3 (0–12) | |
| SLICC-SDI score: median (range) | 1 (0–7) | |
| Medications (ever exposed) | ||
| Hydroxychloroquine | 89 | 94 |
| Prednisolone | 75 | 79 |
| Mycophenolate | 45 | 47 |
| Azathioprine | 37 | 39 |
| Methotrexate | 23 | 24 |
| Leflunomide | 5 | 5 |
| Rituximab | 5 | 5 |
| Cyclophosphamide | 3 | 3 |
| Prednisolone dose (at test): median (range) | 0 mg (0–50) | |
Serology was recorded as ever positive for each patient, usually ordered at baseline.
APLS antibodies (anti-cardiolipin, beta-2 glycoprotein and lupus anticoagulant).
APLS, antiphospholipid syndrome; dsDNA, double-stranded DNA; SLEDAI-2K, SLE Disease Activity Index 2000; SLICC-SDI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index.